Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

[1]  A. Vcev,et al.  Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[2]  E. Bortey,et al.  Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial , 2010, Alimentary pharmacology & therapeutics.

[3]  J. Korzenik,et al.  Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. , 2010, Gastroenterology.

[4]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[5]  P. Rutgeerts,et al.  Importance of mucosal healing in ulcerative colitis , 2010, Inflammatory bowel diseases.

[6]  M. Dubinsky,et al.  The Impact of Ulcerative Colitis on Patients’ Lives Compared to Other Chronic Diseases: A Patient Survey , 2010, Digestive Diseases and Sciences.

[7]  M. Campieri,et al.  Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.

[8]  G. Lichtenstein.  Mucosal healing in ulcerative colitis: Investigating the correlation between healing of the colonic mucosa and clinical outcomes: P-0024. , 2008 .

[9]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[10]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[11]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[12]  P. Rutgeerts,et al.  Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? , 2007, Gut.

[13]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[14]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[15]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  E. Loftus.  A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies , 2006, Inflammatory bowel diseases.

[17]  O. Dewit,et al.  Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study , 2006, Alimentary pharmacology & therapeutics.

[18]  H. Leufkens,et al.  5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study , 2005, Gut.

[19]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.

[20]  J. Eaden.  Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[21]  W. Sandborn,et al.  Epidemiology of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[22]  Hiroshi Nishiyama,et al.  Points to consider on switching between superiority and non-inferiority. , 2006, British journal of clinical pharmacology.

[23]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[24]  Taylor,et al.  Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months , 1998, Alimentary pharmacology & therapeutics.

[25]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[26]  G. Porro,et al.  Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. , 1995, Journal of clinical gastroenterology.

[27]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis , 1995 .

[28]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. , 1995, European journal of gastroenterology & hepatology.

[29]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. , 1995, Digestive diseases and sciences.

[30]  E. O'Keefe,et al.  Olsalazine in maintenance of clinical remission in patients with ulcerative colitis , 1993, Digestive diseases and sciences.

[31]  P. Blok,et al.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. , 1988, Gastroenterology.

[32]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[33]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Gut.

[34]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[35]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[36]  S. Truelove,et al.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.